oppn parties A Setback For The AstraZeneca-Oxford University Covid Vaccine

News Snippets

  • Supreme Court questions the continuing relevance of two-child norms. The Court observed that falling fertility rates have weakened the population-control rationale behind laws disqualifying people with more than two children from contesting local body elections. It referred the issue to a larger Bench for consideration
  • Supreme Court declines to shift Tirupati laddu case outside Andhra Pradesh. The Court rejected a plea seeking transfer of the trial, despite arguments that political statements by Andhra Pradesh's Chief Minister and Deputy Chief Minister could affect the fairness of proceedings
  • Supreme Court transfers Azam Khan's fresh ED bail plea to Allahabad High Court. The apex court declined to consider the Samajwadi Party leader's bail request in a fresh Enforcement Directorate case and directed that it be listed before a division Bench of the High Court on November 16
  • Two killed in Delhi building collapse; contractor booked. Two bodies were recovered after a building collapsed in Chawri Bazaar. Delhi Chief Minister Rekha Gupta said the contractor had been booked and the concerned junior and assistant engineers suspended
  • Uttar Pradesh voter rolls show a 2.4-crore discrepancy. A difference of approximately 2.4 crore names has been reported between the state's panchayat and rural Assembly voter lists. The Election Commission has ordered the two sets of rolls to be matched
  • Gujarat announces 3% dearness allowance hike. The state government announced a three-percentage-point increase in dearness allowance for government employees and pensioners ahead of Diwali
  • Sensex and Nifty post their strongest single-day gains in months. The Sensex surged 2,008.61 points, or 2.60%, to close at 79,310.01, while the Nifty 50 climbed 576 points, or 2.40%, to 24,536.60. Financial and automobile stocks led the rally, supported by falling crude prices and renewed foreign investor buying
  • Maaya Rajeshwaran reaches WTA-level quarter-final. The 17-year-old Indian defeated Poland's Weronika Falkowska 6-4, 6-3, becoming the first Indian woman since Sania Mirza in 2012 to reach a quarter-final at a WTA Tour-level singles event
  • Tanvi Patri reaches Youth Olympics badminton final. The 15-year-old defeated Japan's Yuzuno Watanabe in the semi-final, assuring India of a medal and becoming the first Indian badminton player to reach the girls' singles final at the Youth Olympics
  • India beat Pakistan 3-2 in SAFF Championship. India defeated Pakistan in a closely contested match, having led 3-0 before conceding two late goals. The victory was reported as a significant result for India's second-string side
  • India beat Japan 4-1 to win a record sixth Asian Champions Trophy. India recovered from an early deficit to defeat Japan in the final at Mohali, extending its record as the tournament's most successful men's team
  • The Supreme Court issued notice to the Centre and the Election Commission on a petition challenging Section 16 of the Chief Election Commissioner and Other Election Commissioners Act, 2023, which grants the CEC and Election Commissioners protection from legal proceedings for acts performed in their official duties. The petition argues that such blanket immunity could leave citizens without an effective remedy for alleged wrongdoing by the Commission
  • The Supreme Court told voters whose names were deleted from Delhi's draft electoral rolls not to be apprehensive about seeking re-enrolment through Form 6, after the Election Commission assured it that such applicants would not be prosecuted merely because their names had appeared in earlier rolls
  • Congress leader Rahul Gandhi opened the party's campaign for the 2027 Punjab Assembly elections with an Insaaf rally in Sangrur, Chief Minister Bhagwant Mann's home district, accusing the AAP government of failing to control drugs, gangster violence and corruption. Congress president Mallikarjun Kharge outlined six commitments, including a drug-free Punjab, protection of farmers, employment for young people and action against corruption
  • Rahul Gandhi accused the AAP government of running Punjab through a remote control from Delhi and questioned Bhagwant Mann's ability to tackle drug abuse, making personal allegations about the Chief Minister's conduct during their time together in Parliament
Stock markets on fire due to US results, Sensex gains 2008 points to reach its highest level in 8 months
oppn parties
A Setback For The AstraZeneca-Oxford University Covid Vaccine

By Sunil Garodia
First publised on 2020-09-12 08:47:41

About the Author

Sunil Garodia Editor-in-Chief of indiacommentary.com. Current Affairs analyst and political commentator. Author of Cyber Scams in India, Digital Arrest, The Money Trap and The Human Hack

There are no shortcuts in developing new vaccines or drugs. This fact was forcefully brought in focus when AstraZeneca and Oxford University suspended the ongoing Phase 3 trials of their Covid vaccine after a volunteer in the UK developed inflammation in her spinal cord. Serum Institute, which was conducting the trials for the said vaccine in India and was getting ready to produce it on a huge scale, has also stopped the trials. This also shows that the race to develop the vaccine is unholy, especially the US announcement that the vaccine will be available for mass administration from the first week of November.

The coronavirus pandemic has brought untold miseries upon the human race. It has brought economies to a standstill and has caused severe loss of production and income due to lockdowns. Governments all over the world are grappling to provide relief to people whose jobs are gone and income is squeezed. In such a scenario, it is important that a vaccine or a drug to treat the disease is developed at the earliest. But does that mean that pharmaceuticals companies, guided by the profit motive, will throw all norms to the wind?

Developing a new vaccine or drug is a long drawn out process and can take anywhere between 9 to 18 months or longer before it can be certified as safe and effective. There are numerous stages of trials. Volunteers are needed for each stage. After every stage, the results need to be collated, studied and submitted for regulatory approvals. The next stage can be started only after approval of the results of the earlier stage. There are no shortcuts.

Although vaccines and drugs for all new diseases have had their share of setbacks and the time taken to release them in the market has many times overshot the initially expected deadline, the Covid vaccine is being awaited expectantly all over the world. Russia has already released one in the market. But all other developers are in various stages of trial. The AstraZeneca-Oxford University was considered a frontrunner. But the unfortunate hiccup in the trails will now be vetted by an independent panel. The trials will resume only after the cause is identified and corrective measures are taken. This effectively pushes the vaccine back by at least three months. In any case, is it not better to receive a safe and effective vaccine later rather than experiment with a half-baked one now, one that can endanger lives?